Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

OBJECTIVES: SPIRIT head-to-head (H2H) is a 52-week (Wk) trial comparing ixekizumab (IXE) with adalimumab (ADA) for simultaneous American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses in 566 patients (distributed evenly across both groups) with psoriatic ar...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Rheum Dis
Asıl Yazarlar: Smolen, Josef S, Mease, Philip, Tahir, Hasan, Schulze-Koops, Hendrik, de la Torre, Inmaculada, Li, Lingnan, Hojnik, Maja, Sapin, Christophe, Okada, Masato, Caporali, Roberto, Gratacós, Jordi, Goupille, Philippe, Liu Leage, Soyi, Pillai, Sreekumar, Nash, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Psoriatic Arthritis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509529/
https://ncbi.nlm.nih.gov/pubmed/32660977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217372
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller